CompletedNot Applicable

New Predictors in Determining the Need for Invasive Treatment in Non-STEMI

Turkey (Türkiye)276 participantsStarted 2018-01-01

Plain-language summary

Non-ST elevation acute coronary syndrome (NSTE-ACS) is a heterogeneous disease with a wide range of treatment options from the medical follow-up to early invasive treatment due to complete occlusion of the culprit artery. Non-ST elevation myocardial infarction acute coronary syndrome (NSTEMI-ACS) is one of the subcomponents of NSTE-ACS, which has an increased mortality rate, and for which early intervention can be vital. Yet, most of these patients require invasive treatment. In fact, some of them are patients who require very early invasive treatment and have a complete occlusion in the culprit artery. Unfortunately, risk scoring systems are not sufficient enough to differentiate these patients. Therefore, the discovery of markers that can be used in the differentiation of NSTEMI-ACS patients with an increased need for invasive treatment and/or complete occlusion of the culprit's vessels, especially during pandemic periods such as the COVID-19 pandemic, has gained importance. Inflammation is known to play an important role in the etiopathogenesis of coronary artery disease. To the best of our knowledge, there is a lack of literature on the relationship between the need for invasive treatment strategy and/or complete occlusion of the culprit's vessel, and the hematological markers in patients diagnosed with NSTEMI-ACS.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * NonST elevated myocard ınfarctus * Elder than 18 years * Patients who were not have the exclusion criterias Exclusion Criteria: * Under the age of 18, * Recurrent or ongoing chest pain resistant to drug therapy, * Hemodynamic instability, * Life-threatening ventricular arrhythmias or cardiac arrest, * Development of mechanical complications and the presence of dynamic ST-T wave changes (intermittent ST-segment elevation), * Heart failure, * Ejection fraction \<40, * Severe anemia, * Sepsis, * Malignancy, * Chronic hematological disease, * Collagen tissue disease * Obesity, * Moderate to severe hepatic failure, * Renal failure (Glomerular filtration rate \<60 ml/min/1.73 m2), * Severe valvular heart disease, * Electrolyte disturbance, * Chronic anti-inflammatory drug use, * History of chronic inflammatory disease, * A history of serious infection in the last month * Patients with missing data

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1This trial studied new predictors in the blood to help decide whether patients with Non-STEMI need an invasive procedure — could the blood markers they identified in this research apply to my situation, and would my doctor consider using them to guide my treatment decisions?
2Since this trial has already been completed, has my doctor seen or reviewed its findings, and do those findings change anything about how they would assess whether I need an invasive intervention like angiography or stenting?
3The trial focused on Non-STEMI specifically — given that my diagnosis also falls in this category, how does my doctor currently decide when invasive treatment is necessary, and does it align with what this study was trying to improve upon?
4Are there standard scoring tools or blood tests already in use for Non-STEMI decision-making, and how might the new predictors from this research compare to or complement what my care team is already doing?
5Since this was an observational or diagnostic study rather than a treatment trial, does my doctor think the results could realistically affect how soon or how aggressively my condition should be treated, or is it more relevant to future patients than to my care right now?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Predictive factors for Non ST elevated MI Blood prarameters Predictive factors for Non ST eleveted MI

Timeframe: Pretreatment period

Trial details

NCT IDNCT04763213

SponsorKahramanmaras Sutcu Imam University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-12-31

View on ClinicalTrials.gov More Myocard Infarctus trials